These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38132469)

  • 1. Advocacy of Precision Allergy Molecular Diagnosis in Decision Making for the Eligibility of Customized Allergen Immunotherapy.
    González-Pérez R; Poza-Guedes P; Pineda F; Sánchez-Machín I
    Curr Issues Mol Biol; 2023 Dec; 45(12):9976-9984. PubMed ID: 38132469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis.
    Zhao L; Zhang Y; Zhang S; Zhang L; Lan F
    Expert Rev Clin Immunol; 2021 Sep; 17(9):969-975. PubMed ID: 34388949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mapping of Allergen Exposome among Different Atopic Phenotypes.
    González-Pérez R; Poza-Guedes P; Pineda F; Galán T; Mederos-Luis E; Abel-Fernández E; Martínez MJ; Sánchez-Machín I
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. House Dust Mite Precision Allergy Molecular Diagnosis (PAMD@) in the Th2-prone Atopic Dermatitis Endotype.
    González-Pérez R; Poza-Guedes P; Pineda F; Castillo M; Sánchez-Machín I
    Life (Basel); 2021 Dec; 11(12):. PubMed ID: 34947948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens.
    Potapova E; Bordas-Le Floch V; Schlederer T; Vrtala S; Huang HJ; Canonica GW; Valenta R; Matricardi PM; Mascarell L
    Allergy; 2022 Oct; 77(10):3084-3095. PubMed ID: 35474582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between sensitization to house dust mite major allergens, age, and symptoms in Japanese house dust mite allergic subjects.
    Hasegawa A; Utsumi D; Lund K; Okano M; Ohashi-Doi K; Okubo K
    Int Immunopharmacol; 2022 Jun; 107():108640. PubMed ID: 35217338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines.
    Larenas-Linnemann D; Rodríguez-Pérez N; Luna-Pech JA; Rodríguez-González M; Blandón-Vijil MV; Del-Río-Navarro BE; Costa-Domínguez MDC; Navarrete-Rodríguez EM; Macouzet-Sánchez C; Ortega-Martell JA; Pozo-Beltrán CF; Estrada-Cardona A; Arias-Cruz A; Rodríguez Galván KG; Brito-Díaz H; Canseco-Raymundo MDR; Castelán-Chávez EE; Escalante-Domínguez AJ; Gálvez-Romero JL; Gómez-Vera J; González-Díaz SN; Guerrero-Núñez MGB; Hernández-Colín DD; Macías-Weinmann A; Mendoza-Hernández DA; Meneses-Sánchez NA; Mogica-Martínez MD; Moncayo-Coello CV; Montiel-Herrera JM; O'Farril-Romanillos PM; Onuma-Takane E; Ortega-Cisneros M; Rangel-Garza L; Stone-Aguilar H; Torres-Lozano C; Venegas-Montoya E; Wakida-Kusunoki G; Partida-Gaytán A; López-García AI; Macías-Robles AP; Ambriz-Moreno MJ; Azamar-Jácome AA; Beltrán-De Paz CY; Caballero-López C; Fernández de Córdova-Aguirre JC; Fernández-Soto JR; Lozano-Sáenz JS; Oyoqui-Flores JJ; Osorio-Escamilla RE; Ramírez-Jiménez F; Rivero-Yeverino D; Martínez Infante E; Medina-Ávalos MA
    World Allergy Organ J; 2020 Aug; 13(8):100444. PubMed ID: 32884611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy comparison and safety analysis of subcutaneous specific immunotherapy with standardized house dust mite allergen in patients with single and multiple allergic rhinitis].
    Huang HH; Xu C; Liu L; Chai RN
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jun; 56(6):774-783. PubMed ID: 35785859
    [No Abstract]   [Full Text] [Related]  

  • 10. Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: Subgroup analyses of the REACT study.
    Contoli M; Porsbjerg C; Buchs S; Larsen JR; Freemantle N; Fritzsching B
    J Allergy Clin Immunol; 2023 Aug; 152(2):445-452.e4. PubMed ID: 36871918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Results of Specific IgE in 100 Atopic Dermatitis Patients with the Use of Multiplex Examination ALEX2-Allergy Explorer.
    Čelakovská J; Bukač J; Cermákova E; Vaňková R; Skalská H; Krejsek J; Andrýs C
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific IgE against the house dust mite allergens Der p 5, 20 and 21 influences the phenotype and severity of atopic diseases.
    Walsemann T; Böttger M; Traidl S; Schwager C; Gülsen A; Freimooser S; Roesner LM; Werfel T; Jappe U
    Allergy; 2023 Mar; 78(3):731-742. PubMed ID: 36239002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: Results from the REACT study, a retrospective cohort study.
    Fritzsching B; Contoli M; Porsbjerg C; Buchs S; Larsen JR; Elliott L; Rodriguez MR; Freemantle N
    Lancet Reg Health Eur; 2022 Feb; 13():100275. PubMed ID: 34901915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Profile Sensitization to House Dust Mites as an Important Aspect for Predicting the Efficiency of Allergen Immunotherapy.
    Rodinkova VV; Yuriev SD; Kryvopustova MV; Mokin VB; Kryzhanovskyi YM; Kurchenko AI
    Front Immunol; 2022; 13():848616. PubMed ID: 35392080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial.
    Bożek A; Kołodziejczyk K; Kozłowska R; Canonica GW
    Clin Transl Allergy; 2017; 7():43. PubMed ID: 29214012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mite-Allergic Rhinitis: How to Evaluate Clinical Efficacy in Allergen-Specific Immunotherapy Trials?
    Pfaar O; Gerth van Wijk R
    Curr Treat Options Allergy; 2015; 2(1):1-9. PubMed ID: 25798370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological analysis of allergic components of house dust mite provides more insight in epidemiological characteristics and clinical symptom development in North China.
    Liu Y; Zhao L; Wang J; Guo Y; Wang Y; Zhang L; Wu Z; Zhu M; Yang X; Xu P; Wu S; Gao Z; Sun JL
    Front Immunol; 2023; 14():1083755. PubMed ID: 37180108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. House dust mite subcutaneous immunotherapy in Chinese patients with allergic asthma and rhinitis.
    Feng M; Zeng X; Li J
    J Thorac Dis; 2019 Aug; 11(8):3616-3625. PubMed ID: 31559069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.
    Agache I; Lau S; Akdis CA; Smolinska S; Bonini M; Cavkaytar O; Flood B; Gajdanowicz P; Izuhara K; Kalayci O; Mosges R; Palomares O; Papadopoulos NG; Sokolowska M; Angier E; Fernandez-Rivas M; Pajno G; Pfaar O; Roberts GC; Ryan D; Sturm GJ; van Ree R; Varga EM; van Wijk RG; Yepes-Nuñez JJ; Jutel M
    Allergy; 2019 May; 74(5):855-873. PubMed ID: 31095767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.